Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance -: In Reply

被引：0
|
作者：
Lipton, A [1 ]
Leitzel, K
Demers, L
Harvey, HA
Ali, SM
Chaudri-Ross, HA
Wyld, P
Brady, C
Carney, W
机构：
[1] MS Hershey Med Ctr, Hershey, PA USA
[2] Vet Adm Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Bayer Corp, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 24期
关键词：
D O I：
10.1200/JCO.2003.99.187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4657 / 4657
页数：1
相关论文
共 50 条
  • [31] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Maged Mansour
    Cynthia Mourad
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 429 - 435
  • [32] Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    Osborne, CK
    Bardou, V
    Hopp, TA
    Chamness, GC
    Hilsenbeck, SG
    Fuqua, SAW
    Wong, JM
    Allred, DC
    Clark, GM
    Schiff, R
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) : 353 - 361
  • [33] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Gillian M. Keating
    Drugs, 2012, 72 : 353 - 360
  • [34] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    DRUGS, 2012, 72 (03) : 353 - 360
  • [35] Her-2/neu oncoprotein serum levels in patients with breast cancer:: Comparison with CEA and CA 15.3
    Molina, R.
    Auge, J. M.
    Munoz, M.
    Pahisa, J.
    Torne, A.
    Velasco, M.
    Farrus, B.
    Filella, X.
    TUMOR BIOLOGY, 2007, 28 : 21 - 21
  • [36] HER-2/NEU Oncoprotein Serum Levels in Patients with Breast Cancer: Comparison with CEA and CA 15.3
    Molina, R.
    Auge, J. M.
    Munoz, M.
    Pahisa, J.
    Torne, A.
    Velasco, M.
    Farrus, B.
    Filella, X.
    TUMOR BIOLOGY, 2008, 29 : 34 - 34
  • [37] A comparison of the efficacy of trastuzumab and chemotherapy combination as a first or second-line treatment regimen in metastatic, HER-2/neu overexpressed breast cancer patients
    Bauer-Kosinska, Barbara
    Lemanska, Izabella
    Glogowska, Iwona
    Pienkowski, Tadeusz
    ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
  • [38] Study of serum EGFR, HER-2/neu, VEGF in metastatic breast cancer patients treated with taxanes.
    Labropoulos, SV
    Fountzilas, G
    Papadopoulos, S
    Karina, M
    Xylouri, M
    Doudoulakakis, A
    Chalkidou, S
    Razis, ED
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 66S - 66S
  • [39] High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer
    Jensen, BV
    Johansen, JS
    Price, PA
    CLINICAL CANCER RESEARCH, 2003, 9 (12) : 4423 - 4434
  • [40] Clinical utility of an automated serum HER-2/neu assay in monitoring patients with metastatic breast cancer.
    Dai, J
    Morris, DL
    Neaman, IE
    Carney, W
    Tenny, D
    Yeung, KK
    Allard, WJ
    Chan, DW
    Schwartz, MK
    CLINICAL CHEMISTRY, 1998, 44 : A47 - A47
12345